What is PCOS, and why does its renaming to PMOS matter? An AIIMS doctor explains

As of 12 May 2026, Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), announced in *The Lancet* — ...

What Happened

As of 12 May 2026, Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), announced in The Lancet — one of the world's leading medical journals.
The renaming followed a 14-year global consensus process led by Professor Helena Teede of Monash University, with input from 56 professional medical societies and thousands of patients across six continents.
The new name PMOS reflects the condition's true nature: it is fundamentally a hormonal (polyendocrine) and metabolic disorder, not merely a disease of ovarian cysts as the old name implied.
The old name had led to decades of misdiagnosis and under-treatment: up to 70% of affected individuals were not diagnosed, as healthcare providers and patients alike associated the condition only with cysts.
Rollout of the new terminology is planned over 3 years, with updates to clinical guidelines used in 195 countries. The condition affects over 170 million people worldwide.

Static Topic Bridges

What is PMOS (formerly PCOS)?

Polycystic Ovary Syndrome (PCOS), now renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), is the most common endocrine (hormonal) disorder in women of reproductive age worldwide.

Old name: Polycystic Ovary Syndrome (PCOS) — coined because early imaging showed multiple small follicles (mistakenly called 'cysts') on ovaries
New name breakdown:
Poly-endocrine: Affects multiple hormonal systems simultaneously — insulin signalling, androgen (male sex hormone) production, and neuroendocrine pathways
Metabolic: Insulin resistance is common even in those at a healthy weight; metabolic syndrome, Type 2 diabetes risk, and cardiovascular risk are core features
Ovarian: The ovaries remain involved (anovulation, hormonal production), but the condition is not defined primarily by ovarian cysts
Diagnostic criteria (Rotterdam Criteria — still used): Two of three features required: (1) hyperandrogenism (excess male hormones), (2) ovulatory dysfunction (irregular/absent periods), (3) polycystic ovarian morphology on ultrasound
Global prevalence: Affects 8–13% of women of reproductive age worldwide; 170+ million individuals globally

Connection to this news: The renaming corrects the fundamental misconception built into PCOS's name — the condition is systemic, not ovary-centric.

Medical terminology directly shapes clinical practice, research funding allocation, patient self-understanding, and diagnostic pathways.

The word "polycystic" caused widespread confusion: many women without ovarian cysts were told they did not have PCOS; many with incidental cysts were over-diagnosed
Diagnostic delay: Studies show up to 70% of PCOS cases globally go undiagnosed — a failure tied partly to naming confusion and partly to fragmented care (patients seen by gynaecologists only, missing metabolic features)
The new name PMOS is designed to signal to endocrinologists, metabolic physicians, and cardiologists — not just gynaecologists — that this is a multi-system disorder requiring multi-disciplinary management
Women with PMOS have elevated lifetime risks for: Type 2 diabetes, metabolic syndrome, cardiovascular disease, endometrial cancer, depression, and anxiety
Fertility implications: PMOS is a leading cause of anovulatory infertility (failure to ovulate), but it is treatable

Connection to this news: This renaming is as much a public health intervention as a scientific update — correcting a name that has measurably harmed patient outcomes for over 80 years.

PMOS in India — Public Health Context

Indian prevalence: Studies report PCOS/PMOS prevalence ranging from 2%–36% among women of reproductive age in India, with some estimates suggesting 1 in 5 young Indian women are affected
PMOS is the most common endocrine disorder in Indian women of reproductive age
Underdiagnosis is severe in India: low health literacy, rural healthcare gaps, stigma around menstrual irregularity, and lack of specialist access leave most cases untreated
Adolescents and rural women are particularly vulnerable
Metabolic complications (insulin resistance, obesity, dyslipidaemia, non-alcoholic fatty liver disease) are highly prevalent among Indian PMOS patients
India lacks a national PMOS screening or management programme; care is fragmented between gynaecologists and general practitioners

Connection to this news: The renaming is expected to trigger updates to Indian clinical guidelines (as part of the 195-country rollout), potentially improving diagnostic rates in a country where the burden is high but awareness remains low.

Insulin Resistance — A Core Mechanism

Insulin resistance: Body's cells do not respond effectively to insulin → pancreas compensates by producing more insulin (hyperinsulinaemia)
Excess insulin in PMOS stimulates the ovaries to produce more androgens (e.g., testosterone) → hormonal imbalance
The metabolic-reproductive feedback loop makes PMOS a systemic endocrine disorder, not a purely reproductive one
PMOS is associated with increased risk of Type 2 diabetes: 10–20x higher risk than age-matched controls
Management of insulin resistance (diet, exercise, metformin) is now a primary treatment pillar — not just hormonal contraceptives as historically prescribed

Connection to this news: The new name PMOS explicitly includes "Metabolic" to ensure insulin resistance and its consequences are recognised and treated, not just the reproductive symptoms.

Global Consensus Processes in Medicine — Policy Relevance

The PMOS renaming is a rare example of a global, evidence-based consensus renaming in medicine
Led by Monash University's Professor Helena Teede through a formal Delphi consensus process — involving patients, clinicians, researchers, and 56 professional societies
Published in The Lancet (12 May 2026) — the official record that triggers adoption in national guidelines
3-year rollout timeline covers: ICD (International Classification of Diseases) updates, national clinical guidelines in 195 WHO member states, medical education curricula, and patient-facing materials
AIIMS (All India Institute of Medical Sciences) is involved in India's advisory process for updating Indian guidelines to reflect the new nomenclature

Connection to this news: For UPSC, this illustrates how science-policy interfaces work in global health: research consensus → journal publication → international body (WHO/ICD) update → national guideline revision → healthcare delivery reform.

Key Facts & Data

Old name: Polycystic Ovary Syndrome (PCOS)
New name: Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Announcement date: 12 May 2026 (published in The Lancet)
Consensus process duration: 14 years
Organisations involved: 56 professional medical societies, patients from 6 continents
Global burden: 170+ million people worldwide (8–13% of women of reproductive age)
Undiagnosed proportion: Up to 70% globally
India prevalence: Up to 36% in some studies; 1 in 5 young women estimated affected
Rollout timeline: 3 years; updates to guidelines in 195 countries
PMOS raises Type 2 diabetes risk by 10–20x compared to general population
Leading cause of anovulatory infertility globally
Core features (Rotterdam Criteria): hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology (2 of 3 required for diagnosis)